[go: up one dir, main page]

Cherradi et al., 2018 - Google Patents

Filter-based clarification of viral vaccines and vectors

Cherradi et al., 2018

View PDF
Document ID
5290466069073546057
Author
Cherradi Y
Le Merdy S
Sim L
Ito T
Pattnaik P
Haas J
Boumlic A
Publication year
Publication venue
BioProcess International

External Links

Snippet

50 BioProcess International 16 (4) A 2018 SS method selected (eg, chemical or mechanical), if applicable—the impurity profile in the fluid to be clarified can differ considerably. For example, low cell viability can indicate high levels of contaminants …
Continue reading at www.merckmillipore.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae

Similar Documents

Publication Publication Date Title
Moleirinho et al. Current challenges in biotherapeutic particles manufacturing
US11268071B2 (en) Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
CN107567496B (en) Aseptic purification methods for viruses
NZ330131A (en) Influenza vaccine having less than 25pg per dose of host cell dna content, surface antigen proteins from influenza viruses
Do Minh et al. Critical assessment of purification and analytical technologies for enveloped viral vector and vaccine processing and their current limitations in resolving co-expressed extracellular vesicles
Carvalho et al. Efficient filtration strategies for the clarification of influenza virus-like particles derived from insect cells
AU2013208187B2 (en) Purification of flaviviruses
US20210254021A1 (en) Integrated manufacturing and chromatographic system for virus production
US12305198B2 (en) Virus purification and formulation process
CN106574252B (en) Method for purifying poliovirus from cell culture
Cherradi et al. Filter-based clarification of viral vaccines and vectors
CA2859916A1 (en) Purification of herpes virus
CN107043784A (en) A kind of preparation method of slow virus carrier
KR102245547B1 (en) Method for the clarification of high density crude cell culture harvest
Lothert Steric exclusion chromatography: Advancement of a laboratory-based platform technology into a key component of viral vector and vaccine production processes
Kröber et al. DNA Depletion by precipitation in the purification of cell culture‐derived influenza vaccines
Vergauwen et al. Filtration Principles and Techniques for Bioprocessing of Viral Vector-Based Therapeutics
Schimek et al. Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses
Gränicher Process intensification and integration for the production of vaccines and viral vectors
Weigel Development of chromatography-based purification processes for cell culture-derived influenza virus particles
CN117625558A (en) Preparation method of influenza virus split vaccine
Chrisdianto et al. INDONESIAN JOURNAL OF LIFE SCIENCES
Kalbfuß-Zimmermann Downstream processing of influenza whole-virions for vaccine production